Antengene doses first patient in ATG-019 trial to treat solid tumors
Category: #healthcare  By Mateen Dalal  Date: 2020-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Antengene doses first patient in ATG-019 trial to treat solid tumors
  • The study aims at analyzing the tolerability and safety of ATG-019 monotherapy or in combination with niacin ER
  • Antengene is also exploring the potential of ATG-019 in the treatment of various other indications

Antengene has reportedly announced the dosing of the first patient in Taiwan for its Phase 1 clinical study of ATG-019, a dual inhibitor of NAMPT and PAK4.

Reportedly, the trial is being carried out to analyze the tolerability and safety of ATG-019 monotherapy or ATG-019 along with niacin ER towards the treatment of non- Hodgkin’s lymphoma or solid tumors.

For the record, ATG-019 is a leading, orally bioavailable dual-target drug targeting both nicotinamide phosphoribosyl transferase and p21- activated kinase 4. PAK4 helps in regulating various fundamental cellular procedures, comprising of cellular division, intracellular transport, immune defense, cell shape and motility and the occurrence of cancer.

Additionally, PAK 4 interacts with various signaling molecules that are involved in the development of cancer like CDC42, beta-catenin, BAD, myosin light chain and Raf-1.

Apparently, the overactivation and overexpression of PAK4 have led to a rise in tumor and metastasis along with showcasing a negative correlation with the infiltration of immune cells that may lead to an increase in tumor along with metastasis. NAMPT, on the other hand, is a rate-limiting enzyme in the metabolic scavenging process that uses nicotinamide to reload nicotinamide dinucleotide, a necessary metabolic cofactor and second messenger. The inhibition of NAMPT carries the ability to inhibit the energy metabolisms and the development of tumor cells.

Citing reliable sources, Antengene signed a strategic collaboration with U.S. based Karyopharm Therapeutics Inc. in May 2018 and gained exclusive rights towards the development and commercialization of four clinical-stage, oral drugs including KPT-9274, in several Asian nations and regions.  

Notably, ATG-019 is a novel oral small molecule inhibitor with increased targets. They prohibit the occurrence, growth, invasion, and migration of tumors through the specific targeting and inhibition of both NAMPT and PAK4. Preclinical trial has showcased a significant inhibitory effect of ATG-019 on different types of tumors such as lung cancer, leukemia, lymphoma, and multiple myeloma, among others.

 

Source Credits: http://www.antengene.com/article.php?p=727

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AltPep Corporation raises USD 23.15 million in Series A funding round
AltPep Corporation raises USD 23.15 million in Series A funding round
By Mateen Dalal

According to reliable sources, U.S.-based privately held biomedical organization AltPep Corporation ...

Volvo to triple EV production volume at its Belgium facility from 2022
Volvo to triple EV production volume at its Belgium facility from 2022
By Mateen Dalal

Swedish luxury car manufacturer, Volvo AB has announced plans to triple electric vehicle production ...

Lenovo launches new AR smart glasses to improve industrial productivity
Lenovo launches new AR smart glasses to improve industrial productivity
By Mateen Dalal

In a bid to enhance efficiency among industrial workers amidst the alarming increase in distributed ...